Safety and tolerability of preventive treatment options for chronic migraine
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and tolerability of preventive treatment options for chronic migraine
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2021-06-15
DOI
10.1080/14740338.2021.1942839
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- Hypertension: A new safety risk for patients treated with erenumab
- (2021) Suprat Saely et al. HEADACHE
- Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
- (2021) J. Talbot et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and Tolerability of Calcitonin Gene-Related Peptide Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine
- (2021) Fred Cohen et al. PAIN MEDICINE
- Reply to the Letter to the Editor by Kessler Y et al. regarding the manuscript “Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.”
- (2021) Roberta Noseda et al. CEPHALALGIA
- Deprescribing in migraine
- (2021) Paolo Martelletti et al. Expert Opinion On Drug Safety
- Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
- (2020) Hong Deng et al. BMC Neurology
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
- (2020) Lanfranco Pellesi et al. HEADACHE
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
- (2020) Rami Burstein et al. HEADACHE
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Combination therapy in migraine: asset or issue?
- (2020) Paolo Martelletti Expert Review of Neurotherapeutics
- Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study
- (2020) Ashley Alex et al. HEADACHE
- Migraine Treatment in Pregnancy: An American Headache Society Survey
- (2020) Katherine T. Hamilton et al. HEADACHE
- Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
- (2020) Stephen Silberstein et al. JOURNAL OF HEADACHE AND PAIN
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
- (2020) Agustin Melo-Carrillo et al. CEPHALALGIA
- Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
- (2020) Danuta Szkutnik-Fiedler Pharmaceutics
- An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
- (2019) Fayyaz Ahmed et al. JOURNAL OF HEADACHE AND PAIN
- CGRP and the Trigeminal System in Migraine
- (2019) Smriti Iyengar et al. HEADACHE
- Aids to management of headache disorders in primary care (2nd edition)
- (2019) T. J. Steiner et al. JOURNAL OF HEADACHE AND PAIN
- Optimising migraine treatment: from drug-drug interactions to personalized medicine
- (2019) Leda Marina Pomes et al. JOURNAL OF HEADACHE AND PAIN
- FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
- (2019) John F. Rothrock et al. HEADACHE
- Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
- (2019) Messoud Ashina et al. CEPHALALGIA
- Erenumab safety and efficacy in migraine
- (2019) Changyu Zhu et al. MEDICINE
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal
- (2018) A. P. Andreou et al. EUROPEAN JOURNAL OF NEUROLOGY
- Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
- (2018) Andrew M. Blumenfeld et al. JOURNAL OF HEADACHE AND PAIN
- The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy
- (2018) Bianca Raffaelli et al. Neurotherapeutics
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
- (2018) Michail Vikelis et al. JOURNAL OF HEADACHE AND PAIN
- Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
- (2018) Lars Bendtsen et al. JOURNAL OF HEADACHE AND PAIN
- A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
- (2018) Angelo Camporeale et al. BMC Neurology
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on the Pharmacological Treatment of Chronic Migraine
- (2016) Christina Sun-Edelstein et al. Current Pain and Headache Reports
- Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies
- (2016) Sheena K. Aurora et al. HEADACHE
- A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability
- (2016) Richard B. Lipton et al. HEADACHE
- Implant-derived magnesium induces local neuronal production of CGRP to improve bone-fracture healing in rats
- (2016) Yifeng Zhang et al. NATURE MEDICINE
- Chronic migraine: risk factors, mechanisms and treatment
- (2016) Arne May et al. Nature Reviews Neurology
- Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache
- (2016) David M. Simpson et al. NEUROLOGY
- Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention
- (2015) Richard B. Lipton et al. HEADACHE
- Pregnancy outcomes following exposure to onabotulinumtoxinA
- (2015) Mitchell F. Brin et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
- (2014) H.-C. Diener et al. EUROPEAN JOURNAL OF NEUROLOGY
- OnabotulinumtoxinA Successfully Used as Migraine Prophylaxis During Pregnancy: A Case Report
- (2014) Andrew Y. Robinson et al. MILITARY MEDICINE
- Vasodilation out of the picture as a cause of migraine headache
- (2013) Andrew Charles LANCET NEUROLOGY
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
- (2010) SK Aurora et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
- (2010) HC Diener et al. CEPHALALGIA
- Global prevalence of chronic migraine: A systematic review
- (2009) JL Natoli et al. CEPHALALGIA
- A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study
- (2009) Ninan T. Mathew et al. HEADACHE
- The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism
- (2008) D. Naot et al. BONE
- Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment
- (2008) M. E. Bigal et al. NEUROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started